MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Knight Therapeutics Company Profile (CVE:GUD)

Consensus Ratings for Knight Therapeutics (CVE:GUD) (?)
Ratings Breakdown: 1 Hold Rating(s), 3 Buy Rating(s)
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: C$6.50

Analysts' Ratings History for Knight Therapeutics (CVE:GUD)
Show:
DateFirmActionRatingPrice TargetActions
3/6/2015MackieInitiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/2/2015LB SecuritiesReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/24/2014LB SecuritiesReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/20/2014LB SecuritiesInitiated CoverageHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/28/2014NBFInitiated CoverageOutperformC$6.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/28/2014National Bank FinancialInitiated CoverageOutperformC$6.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 8/5/2013 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha